Equity Research · Wednesday, October 14, 2026
UNH Stock Analysis for October 2026
UNITEDHEALTH GROUP INCORPORATED (Delaware)
Price at Analysis
1Y Price Target
$435.00
+15.2%
vs current price
Technical Setup
RSI 48 / neutral MACD
Support context: $255.97. Resistance context: $461.62.
Valuation Snapshot
P/E 19.9x TTM (~18.4x 2026E $20.50) / P/S ~0.75x (on ~$451B annualized revenue)
Market cap $339.76B; revenue $112.7B Q3 2026 (-0.4% YoY).
Risk Watch
Shrinking membership and revenue decline
Q3 revenue -0.4% to $112.7B with declining memberships. Sacrificing lives for margin is defensible short-term but erodes scale advantage and long-term premium base if competitors take share (e.g., ELV, Oscar). Needs to stabilize in 2027.
01 · Summary
Executive Summary
UnitedHealth (UNH) is in the middle of a classic managed-care repair job: Q3 2026 delivered $112.7B revenue (-0.4% YoY) with adjusted EPS of $4.69 (+60.6% YoY, 13.8% beat vs $4.12 consensus), MCR down 150 bps to 88.4%, operating cost ratio down to 12.8%, and 2026 adjusted EPS guidance raised to at least $20.50 from $19.50-$20.00. The beat is real but low-quality in one sense — it came from pricing discipline, benefit design, and pruning unprofitable Medicare Advantage lives while membership shrank and Optum Health remained weak. The market's reaction — open at $397.62, high $399.88, close $377.76 on 12.65M shares — signals the easy rebound from ~$256 to ~$440 is now priced in. We still land bullish, not because it is optically cheap at ~18.4x 2026E and 0.75x sales with a 7.1% FCF yield, but because the margin repair has legs: MA margins moving to upper-half of 2-4%, Optum Rx + Optum Insight strength, AI and value-based care efficiencies, and a credible path for Optum Health margins from ~2% in 2026 toward 4% in 2027 and 6% in 2028. Regulatory, Star ratings, DOJ antitrust, and commercial trend risks cap a hyper-bull call, but at -18.2% below the 52-week high and 20% below Morningstar's $475 fair value, risk/reward favors upside over 1-3 years.
02 · Scenario Modeling
Price Targets
$435.00+15.2%
$575.00+52.2%
1-Year scenario price targets · Dashed line = current price
02 · Scenario Modeling
Scenario Analysis
| Scenario | 1Y Target | 1Y Growth | 3Y Target | 3Y Growth |
|---|---|---|---|---|
↑↑Hyper Bull | $505.00 | +33.7% | $680.00 | +80.0% |
↑Bull | $435.00 | +15.2% | $575.00 | +52.2% |
→Neutral | $390.00 | +3.2% | $475.00 | +25.7% |
↓Bear | $320.00 | -15.3% | $300.00 | -20.6% |
↓↓Hyper Bear | $250.00 | -33.8% | $200.00 | -47.1% |
03 · Fundamentals
Key Financial Metrics
- Earnings Per Share (EPS)
- $4.69 adj Q3 (+60.6% YoY); $20.50+ 2026E guide
- Beta
- ~0.6
- Revenue
- $112.7B Q3 2026 (-0.4% YoY)
- P/E Ratio
- 19.9x TTM (~18.4x 2026E $20.50)
- P/S Ratio
- ~0.75x (on ~$451B annualized revenue)
- Market Cap
- $339.76B
- Net Income
- ~$4.0B Q3 (~$4.56 GAAP EPS)
- Dividend Yield
- ~2.3%
- Short Interest
- N/A (no elevated short data disclosed)
- 52-Week Low
- $255.97
- 52-Week High
- $461.62
02 · Scenario Modeling
Technical Overview
Quant overlays derived from the existing 1Y OHLCV series: trend stack, sigma bands, regression fit, drawdown regime, and a composite signal model.
RSI (14)
47.7
Momentum Stack
1M -1.5% / 3M -9.7%
Volatility Regime
16.8% 20D vol
Regression Fit
-6.5% vs trend
Drawdown Curve
Distance from rolling peak, useful for regime stress and recovery speed.
-13.4%
Trend Regime
neutral
Mixed stack
Composite Signal
neutral
Neutral (-2)
Mean Reversion
neutral
+0.81 sigma
Breakout Status
neutral
Inside channel
Range Percentile
neutral
59th pct
Volume Impulse
bullish
2.29x 20D avg
Quant Dashboard
A compact read on trend persistence, stretch, realized risk, and breakout behavior.
- 1M Return
- -1.5%
- 6M Return
- +20.2%
- 1Y Return
- N/A
- ATR (14)
- $10.33
- 20D Vol
- 16.8%
- 60D Vol
- 21.2%
- Regression R²
- 0.38
- Price Z-Score
- +0.81
- 52W High
- $461.62
- 52W Low
- $255.97
- Range Position
- 59th pct
- Latest Volume
- 12.7M
04 · Research
Micro Analysis
Core insurance margins are inflecting while revenue mix is being intentionally shrunk to improve profitability. Optum diversification helps, but Optum Health and membership losses are the weak spots to watch.
MCR and operating leverage inflection
Q3 MCR 88.4% vs 89.9% prior year (-150 bps) on medical cost management, pricing discipline and benefit design. Operating cost ratio 12.8% vs 13.5%. Earnings from operations $6.6B, operating earnings +45.2% YoY, adjusted EPS +60.6% to $4.69. Two straight quarters of improvement supports turnaround credibility.
Revenue down, EPS up — quality question
Revenue $112.7B declined 0.4% YoY and was essentially flat, beating by only 1.2%. Growth came from cost takeout, not top-line. Membership declines and weakness in Optum Health partially offset Optum Insight and Optum Rx strength. Pruning unprofitable MA lives helps margins but cannot drive long-term growth if membership keeps shrinking.
Optum bifurcation
Optum Rx and Optum Insight cited as strengths with margin expansion and AI-driven growth. Optum Health — the risk-taking provider arm — remains pressured at ~2% margins in 2026. Bull path requires expansion to 4% in 2027 and 6% in 2028 per buy-side models. Failure here leaves consolidated growth dependent on insurance underwriting cycle.
Cash flow and balance sheet support
Q3 cash flows from operations $5.1B, or 1.2x net income (~$4B profit, $4.56 GAAP EPS). FCF yield cited at 7.1%, a 9-year high, providing downside support, dividend coverage (~2.3% yield) and buyback capacity for 390,000-employee colossus with 51M members.
Guidance raise with conservative framing
2026 adjusted EPS guide raised to at least $20.50 (at least +25% growth) from $19.50-$20.00 after $4.69 Q3 beat vs $4.15 FactSet. Morningstar boosting near-term expectations. Management under CEO Steve Hemsley and CFO Wayne DeVeydt emphasizing value-based care and AI taking hold, but 'at least' language leaves room for medical cost re-acceleration.
04 · Research
Macro Analysis
Managed care faces structural medical cost inflation, Medicare Advantage funding/political scrutiny, and regulatory overhang, offset by resilient employer and government-backed demand and a rotation toward value-based care.
Persistent medical cost trend risk
Industry-wide elevated utilization in MA and commercial (outpatient, behavioral, GLP-1s) drove 2025 crisis. UNH MCR at 88.4% still well above historical 82-84% norm. Any re-acceleration in Q4/winter flu or commercial trends would quickly reverse 150 bps gain.
Medicare Advantage policy and Stars pressure
CMS 2027 Part C & D Star Ratings in focus ahead of Q3. Downgrades threaten 2028 bonus revenue and margin recovery. MA margins now toward upper-half of 2-4% range, but reimbursement tightness and risk-adjustment scrutiny create high uncertainty (Morningstar Uncertainty: High).
Regulatory / DOJ antitrust overhang
Scale of UnitedHealthcare + Optum (PBM, care delivery, analytics) invites DOJ antitrust review and PBM reform rhetoric. Limits M&A optionality and could force divestitures or contracting changes, capping multiple expansion despite narrow moat.
Employer-sponsored resilience
Leader in employer, self-directed and government plans provides diversification. Employment remains relatively stable, supporting commercial pricing power and benefit design changes that aided Q3. Self-funded ASO growth less capital intensive.
Market positioning after drawdown
Stock +47.6% off $255.97 low but -18.2% off $461.62 high, RSI 47.7 neutral. Post-earnings fade (open $397.62 to close $377.76) shows sell-the-news after run from $300 to $440-450. Wall Street Strong Buy with ~28% upside target (~$483) contrasts with Seeking Alpha Sell calls that upside is gone — classic late-repair skepticism.
05 · Growth
Untapped Revenue Opportunities
Optum Health margin normalization
highIf risk-based care execution improves, margins expanding from ~2% to 4-6% by 2028 on same revenue base drops disproportionately to EPS. Growing operating footprint after dialing back MA business suggests operating leverage ahead.
Optum Rx and Optum Insight scale
highPharmacy benefit growth (specialty, biosimilars), retention, and Insight analytics/AI services to affiliates and third parties drove Q3 upside. High-margin, less regulated than insurance, supports double-digit operating income growth even with flat premiums.
MA repricing and benefit design
mediumDisciplined bids, benefit reductions, and exit of unprofitable counties/stars-challenged plans lifted MCR 150 bps. Continued 2027 bid discipline plus improved Stars can restore 2-4% MA margins and allow selective membership regrowth in 2027-2028.
06 · Catalysts
Headwinds & Tailwinds
↓ Headwinds
Shrinking membership and revenue decline
highQ3 revenue -0.4% to $112.7B with declining memberships. Sacrificing lives for margin is defensible short-term but erodes scale advantage and long-term premium base if competitors take share (e.g., ELV, Oscar). Needs to stabilize in 2027.
Medical cost re-acceleration
highMCR still elevated at 88.4%. Commercial cost trends flagged as key Q3 focus. Higher acuity, provider rate hikes, and utilization normalization could erase gains and force reserve charges, as seen in 2025 spiral.
Stars, regulation, and litigation
mediumStar rating downgrades hit 2028 revenue, DOJ antitrust/PBM reform and MA audit risk create earnings and multiple overhang. High uncertainty rating reflects binary policy outcomes into election cycle.
↑ Tailwinds
Depressed valuation and FCF yield
highDecade-low P/E ~19.9x TTM (~18.4x 2026E $20.50) vs historic 22-24x compounder premium. 7.1% FCF yield (9-year high) and 1.2x cash conversion support capital returns and floor valuation. Morningstar FV $475, 4-star.
AI and operating efficiency
mediumOperating cost ratio down 70 bps to 12.8% on efficiencies. Optum AI-driven growth in claims, prior-auth, and care management cited by management as taking hold, offering structural SG&A leverage across 390k employees.
Scale moat in diversified healthcare
medium51M global members plus colossus spanning insurance, PBM, outpatient care, analytics creates data, contracting, and cost advantages few can replicate. Narrow moat rating; enables value-based care that competitors lack.
07 · TL;DR
Analysis Summary
- Ticker
- UNH
- Company
- UNITEDHEALTH GROUP INCORPORATED (Delaware)
- Analysis Date
- 2026-10-14
- Price at Analysis
- $377.76
- Rating
- Buy
- 1Y Price Target
- $435.00
- 3Y Price Target
- $575.00
- Market Cap
- $339.76B
- P/E Ratio
- 19.9x TTM (~18.4x 2026E $20.50)
This analysis was generated on 2026-10-14 when UNH was trading at $377.76. The base-case 1-year price target is $435.00 (+15.2% implied return). Scenario range: $250.00 (hyper bear) to $505.00 (hyper bull).